Lumipulse® G sTREM2 Assay
Neuroinflammation
Research Use OnlyLaunched (Jun 2025)
Key Facts
Indication
Neuroinflammation
Phase
Research Use Only
Status
Launched (Jun 2025)
Company
About fujirebio-diagnostics
Fujirebio Diagnostics is an R&D-driven innovator and global provider of in vitro diagnostic solutions, with a mission to create new value in healthcare. Its core achievement is pioneering blood-based biomarkers for Alzheimer's disease, including the first FDA-cleared blood test for amyloid pathology. The company's strategy leverages its proprietary Lumipulse® G platform for internal assay development while operating a synergistic CDMO business, reinvesting partnership revenues to fuel a robust pipeline in neurology, oncology, and infectious diseases.
View full company profileTherapeutic Areas
Other Neuroinflammation Drugs
| Drug | Company | Phase |
|---|---|---|
| Molecular Glue Degrader | Ternary Therapeutics | Pre-clinical |